Sirturo

Drug - Sirturo™ [Janssen]

October 2013

Therapeutic Area - Antituberculosis agents

Approval criteria

• Patient is 18 years of age or older AND
• Patient has a diagnosis of pulmonary multi-drug resistant tuberculosis AND
• Prescriber has reported the case to the Minnesota Department of Health

Quantity limit

Treatment is limited to 24 weeks of therapy.

Background information

SIRTURO™ is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in adults (≥ 18 years) with pulmonary multi-drug resistant tuberculosis (MDR-TB). Reserve SIRTURO™ for use when an effective treatment regimen cannot otherwise be provided. SIRTURO™ is not indicated for the treatment of latent, extra-pulmonary or drug-sensitive tuberculosis or for the treatment of infections caused by non-tuberculous mycobacteria.

Questions?

MHCP Provider Call Center 651-431-2700 or 800-366-5411